IPA as a therapeutic agent, as a protective agent, and as a biomarker of disease risk
Indole-3-propionic acid as a marker and for treatment for Huntington Disease.
1. A method for evaluating oxidative stress in an individual known to be suffering from a disease, comprising obtaining a biological sample from said individual,
subjecting the biological sample to a Fenton reaction in the presence of ubiquitin,
using LC-EC and MS, analyzing said reacted biological sample for the presence of an oxidation product of indole-3-propionic acid bound to ubiquitin, an oxidation product of indole lactic acid bound to ubiquitin, or a ratio of an oxidation product of indole-3-propionic acid bound to ubiquitin/an oxidation product of indole lactic acid bound to ubiquitin, and
comparing said analysis to a standard from an individual known to be suffering from said disease.
2. The method of claim 1 , wherein said individual is human.
3. The method of claim 1 , wherein said biological sample comprises blood or plasma, urine or fecal matter.
4. The method of claim 1 , wherein said LC-EC and MS are employed in parallel.
5. The method of claim 1 , wherein said LC-EC and MS are employed off-line.
6. The method of claim 1 , wherein said biological sample comprises plasma, urine or fecal matter.
7. The method of claim 1 , wherein an individual with a difference in a level of an oxidation product of indole-3-propionic acid bound to ubiquitin or a difference in a level of an oxidation product of indole lactic acid bound to ubiquitin compared to the standard has a neurodegenerative disease.
8. The method of claim 7 , wherein the difference in level is a lower level.
9. The method of claim 7 , wherein the difference in level is a higher level.
10. The method of claim 1 , wherein an individual with a difference in a ratio of an oxidation product of indole-3-propionic acid bound to ubiquitin/an oxidation product of indole lactic acid bound to ubiquitin compared to the standard has a neurodegenerative disease.
11. The method of claim 10 , wherein the difference in ratio is a lower ratio.
12. The method of claim 10 , wherein the difference in ratio is a higher ratio.
13. The method of claim 1 , wherein an individual with a difference in a level of an oxidation product of indole-3-propionic acid bound to ubiquitin or a difference in a level of an oxidation product of indole lactic acid bound to ubiquitin compared to the standard has hypertension, stroke or ischemic heart disease.
14. The method of claim 13 , wherein the difference in level is a lower level.
15. The method of claim 13 , wherein the difference in level is a higher level.
16. The method of claim 1 , wherein an individual with a difference in a ratio of an oxidation product of indole-3-propionic acid bound to ubiquitin/an oxidation product of indole lactic acid bound to ubiquitin compared to the standard has hypertension, stroke or ischemic heart disease.
17. The method of claim 16 , wherein the difference in ratio is a lower ratio.
18. The method of claim 16 , wherein the difference in ratio is a higher ratio.